Prime Medicine Statistics

Total Valuation

Prime Medicine has a market cap or net worth of $381.51 million. The enterprise value is $247.23 million.

Market Cap	381.51M
Enterprise Value	247.23M

Important Dates

The last earnings date was Tuesday, November 12, 2024, after market close.

Earnings Date	Nov 12, 2024
Ex-Dividend Date	n/a

Share Statistics

Prime Medicine has 127.60 million shares outstanding. The number of shares has increased by 26.37% in one year.

Current Share Class	127.60M
Shares Outstanding	127.60M
Shares Change (YoY)	+26.37%
Shares Change (QoQ)	+0.48%
Owned by Insiders (%)	19.98%
Owned by Institutions (%)	47.39%
Float	60.57M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	2.01
P/TBV Ratio	2.01
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	309.04
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 6.50, with a Debt / Equity ratio of 0.22.

Current Ratio	6.50
Quick Ratio	6.09
Debt / Equity	0.22
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-633.30

Financial Efficiency

Return on equity (ROE) is -114.35% and return on invested capital (ROIC) is -60.21%.

Return on Equity (ROE)	-114.35%
Return on Assets (ROA)	-46.51%
Return on Capital (ROIC)	-60.21%
Revenue Per Employee	$3,419
Profits Per Employee	-$936,962
Employee Count	234
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -54.70% in the last 52 weeks. The beta is 2.09, so Prime Medicine's price volatility has been higher than the market average.

Beta (5Y)	2.09
52-Week Price Change	-54.70%
50-Day Moving Average	3.83
200-Day Moving Average	5.49
Relative Strength Index (RSI)	31.16
Average Volume (20 Days)	1,053,267

Short Selling Information

The latest short interest is 15.79 million, so 12.38% of the outstanding shares have been sold short.

Short Interest	15.79M
Short Previous Month	17.64M
Short % of Shares Out	12.38%
Short % of Float	26.08%
Short Ratio (days to cover)	5.78

Income Statement

In the last 12 months, Prime Medicine had revenue of $800,000 and -$219.25 million in losses. Loss per share was -$2.01.

Revenue	800,000
Gross Profit	-161.84M
Operating Income	-212.79M
Pretax Income	-217.55M
Net Income	-219.25M
EBITDA	-207.13M
EBIT	-212.79M
Loss Per Share	-$2.01

Full Income Statement

Balance Sheet

The company has $175.53 million in cash and $41.25 million in debt, giving a net cash position of $134.28 million or $1.05 per share.

Cash & Cash Equivalents	175.53M
Total Debt	41.25M
Net Cash	134.28M
Net Cash Per Share	$1.05
Equity (Book Value)	189.50M
Book Value Per Share	1.49
Working Capital	208.19M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$182.97 million and capital expenditures -$7.34 million, giving a free cash flow of -$190.32 million.

Operating Cash Flow	-182.97M
Capital Expenditures	-7.34M
Free Cash Flow	-190.32M
FCF Per Share	-$1.49

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-26,598.50%
Pretax Margin	-27,406.13%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-34,721.32%

Dividends & Yields

Prime Medicine does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-26.37%
Shareholder Yield	-26.37%
Earnings Yield	-57.47%
FCF Yield	-49.89%

Analyst Forecast

The average price target for Prime Medicine is $13.86, which is 363.55% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$13.86
Price Target Difference	363.55%
Analyst Consensus	Strong Buy
Analyst Count	8
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-11.73%

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Prime Medicine has an Altman Z-Score of -1.22 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.22
Piotroski F-Score	2